Oncobiologics (NASDAQ:OTLK) Stock Rating Lowered by Wall Street Zen

Oncobiologics (NASDAQ:OTLK) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

OTLK has been the subject of several other research reports. HC Wainwright raised their price target on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a report on Monday, July 27th. BTIG Research reissued a “buy” rating and set a $4.00 target price on shares of Oncobiologics in a research note on Friday. Ascendiant Capital Markets boosted their target price on shares of Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Finally, Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.65.

Oncobiologics Stock Performance

Shares of OTLK stock opened at $0.76 on Friday. The stock has a market cap of $112.39 million, a price-to-earnings ratio of -0.98 and a beta of 0.82. The stock has a 50-day moving average of $1.31 and a 200-day moving average of $0.70. Oncobiologics has a 1-year low of $0.16 and a 1-year high of $3.39.

Oncobiologics (NASDAQ:OTLK) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.97 million. Sell-side analysts forecast that Oncobiologics will post -0.49 earnings per share for the current year.

Insider Buying and Selling

In other Oncobiologics news, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was bought at an average cost of $1.05 per share, with a total value of $100,167.90. Following the acquisition, the director owned 220,972 shares in the company, valued at approximately $232,020.60. This represents a 75.97% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ghiath M. Sukhtian acquired 2,525,252 shares of Oncobiologics stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average price of $0.99 per share, with a total value of $2,499,999.48. Following the completion of the purchase, the director directly owned 24,617,320 shares in the company, valued at $24,371,146.80. This represents a 11.43% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,189,359 shares of company stock worth $7,662,666 over the last 90 days. 1.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Oncobiologics

Several institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. lifted its stake in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the last quarter. AQR Capital Management LLC boosted its stake in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after buying an additional 25,351 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after acquiring an additional 21,941 shares during the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

More Oncobiologics News

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.